State Street’s Aprea Therapeutics APRE Stock Holding History

State Street’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,042	Closed	-$13.1K	–	4788
2022 Q4	$13.1K	Hold	2,042	–	–	﹤0.01%	4778
2022 Q3	$27K	Hold	2,042	–	–	﹤0.01%	4782
2022 Q2	$30K	Hold	2,042	–	–	﹤0.01%	4817
2022 Q1	$76K	Hold	2,042	–	–	﹤0.01%	4712
2021 Q4	$117K	Hold	2,042	–	–	﹤0.01%	4541
2021 Q3	$209K	Hold	2,042	–	–	﹤0.01%	4337
2021 Q2	$199K	Sell	2,042 -4,188	-67%	-$387K	﹤0.01%	4212
2021 Q1	$635K	Sell	6,230 -446	-7%	-$52K	﹤0.01%	3702
2020 Q4	$657K	Buy	6,676 +270	+4%	+$128K	﹤0.01%	3618
2020 Q3	$3.08M	Buy	6,406 +259	+4%	+$145K	﹤0.01%	3023
2020 Q2	$4.77M	Buy	6,147 +583	+10%	+$383K	﹤0.01%	2779
2020 Q1	$3.87M	Buy	5,564 +1,308	+31%	+$960K	﹤0.01%	2751
2019 Q4	$3.91M	Buy	+4,256	New	+$2.34M	﹤0.01%	2954

Other funds holding APRE

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street's APRE Position: Q1 2023 in Review

State Street sold out of Aprea Therapeutics (APRE) in Q1 2023, closing a stake of 2,042 shares — an estimated $13.1K sold.

State Street first reported a position in APRE in Q4 2019 and held it in 13 quarters. The position peaked at $4.77M in Q2 2020. 18 funds tracked by Wall St. Rank hold APRE as of Q1 2023.

State Street reported no remaining Aprea Therapeutics position as of Q1 2023 after selling out during the quarter.
State Street sold 2,042 Aprea Therapeutics shares in Q1 2023, an estimated $13.1K.
State Street first reported a position in Aprea Therapeutics in Q4 2019 and held it in 13 quarters.
State Street's Aprea Therapeutics position peaked at $4.77M in Q2 2020.
18 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2023.

Based on State Street's 13F filing for Q1 2023, filed 15 May 2023.